(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 June 2003 (26.06.2003)

PCT

(10) International Publication Number
WO 2003/051380 A3

(51) International Patent Classification[7]: A61K 35/78, 31/12, 31/121, C07C 49/203, 49/647

(21) International Application Number:
PCT/IB2002/005366

(22) International Filing Date:
14 December 2002 (14.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/340,165 14 December 2001 (14.12.2001) US

(71) Applicant *(for all designated States except US)*: **COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH** [IN/IN]; Rafi Marg, 110 001 New Delhi (IN).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **RAY, Madhur** [IN/IN]; Central Drug Research Institute, Manzil Palace, 226 001 Lucknow (Uttar Pradesh) (IN). **PAL, Raghwendra** [IN/IN]; Central Drug Research Institute, Manzil Palace, 226 001 Lucknow (Uttar Pradesh) (IN). **SINGH, Satyawan** [IN/IN]; Central Drug Research Institute, Manzil Palace, 226 001 Lucknow (Uttar Pradesh) (IN). **KHANNA, Nandoo, Mal** [IN/IN]; Central Drug Research Institute, Manzil Palace, 226 001 Lucknow (Uttar Pradesh) (IN).

(74) Agent: **BHOLA, Ravi**; Kumaran & Sagar, 84-C, C-6 Lane, Sainik Farms, 110 062 New Delhi (IN).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*

**Published:**

— *with international search report*

(88) Date of publication of the international search report:
17 June 2004

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 2003/051380 A3

(54) Title: COMPOSITIONS CONTAINEING CURCUMA EXTRACTS FOR THE TREATMENT OF NEUROCEREBROVASCULAR DISORDERS

(57) Abstract: The present invention relates to A composition obtained from the lipid soluble extract of rhizomes and leaves of *Curcuma species* of Zingiberaceae family, useful for the treatment of neurocerebrovascular disorders, said composition comprising fraction A consisting of arturmerone of formula (1), and turmerone of formula (2), and/or along with fraction B consisting of curcumene and zingiberine, and/or fraction C consisting of germacrone, curcumerone, zedoarone, sedoarondiol, isozdedoaronidiol, curcumenone, and curlone, and/or pharmaceutically acceptable additives and a method of treating neurocerebrovascular disorders in animals including humans using said composition by administering therapeutically effective amount of lipid soluble extract.